By Andy Lewis, CRS Director at Large
Somatuline Autogel® is a ready-to-use sustained release formulation of the peptide lanreotide with a unique and innovative controlled release mechanism. Andy Lewis interviewed Joël Richard, VP Peptides at Ipsen, on the background of its development, how it works, and how it is manufactured.
Q What makes lanreotide a good candidate for a sustained release formulation?
A Lanreotide is a potent somatostatin analogue used for the treatment of acromegaly. In acromegaly, the anterior pituitary produces abnormally high levels of growth hormone, often as a result of a tumour of the pituitary gland. The excess growth hormone results in the continued and abnormal growth of the tissues of the body in adulthood.